Molecular diagnostics company
Appears in 1 story
Target company; boards recommend the offer
Swedish buyout firm EQT Private Equity agreed to buy Dutch molecular diagnostics company QIAGEN for €46.50 per share in cash. The offer is a 40.3% premium to QIAGEN's share price before takeover reports surfaced in July, and values the company at about €10.8 billion including roughly $1.1 billion in net debt.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
